☰

Simon Zhornitsky, Ph.D. - Publications

Affiliations: 
2012 Université de Montréal, Montréal, Canada 
Area:
Clinical Psychology, Mental Health
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

24 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Zhornitsky S, Tourjman V, Pelletier J, Assaf R, Li CR, Potvin S. Acute effects of ketamine and esketamine on cognition in healthy subjects: A meta-analysis. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 118: 110575. PMID 35568275 DOI: 10.1016/j.pnpbp.2022.110575  0.463
2021 Zhornitsky S, Chaudhary S, Le TM, Chen Y, Zhang S, Potvin S, Chao HH, van Dyck CH, Li CR. Cognitive dysfunction and cerebral volumetric deficits in individuals with Alzheimer's disease, alcohol use disorder, and dual diagnosis. Psychiatry Research. Neuroimaging. 317: 111380. PMID 34482052 DOI: 10.1016/j.pscychresns.2021.111380  0.432
2021 Le TM, Potvin S, Zhornitsky S, Li CR. Distinct patterns of prefrontal cortical disengagement during inhibitory control in addiction: A meta-analysis based on population characteristics. Neuroscience and Biobehavioral Reviews. 127: 255-269. PMID 33933507 DOI: 10.1016/j.neubiorev.2021.04.028  0.455
2020 Zhornitsky S, Pelletier J, Assaf R, Giroux S, Li CR, Potvin S. Acute effects of partial CB receptor agonists on cognition - A meta-analysis of human studies. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 110063. PMID 32791166 DOI: 10.1016/J.Pnpbp.2020.110063  0.454
2020 Zhornitsky S, Le TM, Dhingra I, Adkinson BD, Potvin S, Li CR. Interpersonal Risk Factors for Suicide in Cocaine Dependence: Association with Self-Esteem, Personality Traits, and Childhood Abuse. Suicide & Life-Threatening Behavior. e12621. PMID 32030810 DOI: 10.1111/Sltb.12621  0.43
2015 Zhornitsky S, Tikàsz A, Rizkallah É, Chiasson JP, Potvin S. Psychopathology in Substance Use Disorder Patients with and without Substance-Induced Psychosis. Journal of Addiction. 2015: 843762. PMID 26417473 DOI: 10.1155/2015/843762  0.569
2015 Potvin S, Zhornitsky S, Stip E. Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 60: S26-34. PMID 25886677  0.465
2013 Stip E, Vincent PD, Sablier J, Guevremont C, Zhornitsky S, Tranulis C. A randomized controlled trial with a Canadian electronic pill dispenser used to measure and improve medication adherence in patients with schizophrenia. Frontiers in Pharmacology. 4: 100. PMID 23950746 DOI: 10.3389/Fphar.2013.00100  0.389
2013 Zhornitsky S, Wee Yong V, Koch MW, Mackie A, Potvin S, Patten SB, Metz LM. Quetiapine fumarate for the treatment of multiple sclerosis: focus on myelin repair. Cns Neuroscience & Therapeutics. 19: 737-44. PMID 23870612 DOI: 10.1111/Cns.12154  0.511
2013 Zhornitsky S, Aubin G, Desfossés J, Rizkallah E, Pampoulova T, Lipp O, Chiasson JP, Stip E, Potvin S. Predictors of community functioning in schizophrenia and substance use disorder patients. Community Mental Health Journal. 49: 317-22. PMID 22847727 DOI: 10.1007/S10597-012-9525-Y  0.602
2012 Zhornitsky S, Potvin S. Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals (Basel, Switzerland). 5: 529-52. PMID 24281562 DOI: 10.3390/Ph5050529  0.573
2012 Zhornitsky S, Rizkallah E, Pampoulova T, Chiasson JP, Lipp O, Stip E, Potvin S. Sensation-seeking, social anhedonia, and impulsivity in substance use disorder patients with and without schizophrenia and in non-abusing schizophrenia patients. Psychiatry Research. 200: 237-41. PMID 22980481 DOI: 10.1016/J.Psychres.2012.07.046  0.604
2012 Moteshafi H, Zhornitsky S, Brunelle S, Stip E. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis. Drug Safety. 35: 819-36. PMID 22967188 DOI: 10.2165/11631510-000000000-00000  0.438
2012 Zhornitsky S, Stip E. Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review. Schizophrenia Research and Treatment. 2012: 407171. PMID 22966436 DOI: 10.1155/2012/407171  0.429
2011 Stip E, Zhornitsky S, Moteshafi H, Létourneau G, Stikarovska I, Potvin S, Tourjman V. Ziprasidone for psychotic disorders: a meta-analysis and systematic review of the relationship between pharmacokinetics, pharmacodynamics, and clinical profile. Clinical Therapeutics. 33: 1853-67. PMID 22133697 DOI: 10.1016/J.Clinthera.2011.10.027  0.554
2011 Zhornitsky S, Stip E, Desfossés J, Pampoulova T, Rizkallah E, Rompré PP, Bentaleb LA, Lipp O, Chiasson JP, Gendron A, Potvin S. Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case-Control Trial with Quetiapine. Frontiers in Psychiatry. 2: 22. PMID 21629845 DOI: 10.3389/Fpsyt.2011.00022  0.631
2011 Zhornitsky S, Potvin S, Moteshafi H, Dubreucq S, Rompré PP, Stip E. Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials. International Clinical Psychopharmacology. 26: 183-92. PMID 21372722 DOI: 10.1097/Yic.0B013E3283430A0E  0.599
2011 Zhornitsky S, Potvin S, Aubin G, Stip E. Relationship between insight into cognition, extrapyramidal symptoms and mental illness in schizophrenia. The Australian and New Zealand Journal of Psychiatry. 45: 604-5. PMID 21355813 DOI: 10.3109/00048674.2011.561483  0.557
2011 Moteshafi H, Zhornitsky S, Dubreucq S, Rompré PP, Potvin S, Stip E. Tolerability of quetiapine across psychiatric disorders International Clinical Psychopharmacology. 26: e149. DOI: 10.1097/01.Yic.0000405887.17709.6D  0.536
2010 Rizkallah E, Stip E, Zhornitsky S, Pampoulova T, Gendron A, Rompré PP, Chiasson JP, Potvin S. Clinical evolution of substance use disorder patients during treatment with quetiapine: a 12-week, open-label, naturalistic trial. Expert Opinion On Pharmacotherapy. 11: 2947-51. PMID 20979569 DOI: 10.1517/14656566.2010.524927  0.603
2010 Zhornitsky S, Stip E, Pampoulova T, Rizkallah E, Lipp O, Bentaleb LA, Chiasson JP, Potvin S. Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 2188-94. PMID 20669315 DOI: 10.1002/Mds.23227  0.614
2010 Zhornitsky S, Rizkallah E, Pampoulova T, Chiasson JP, Stip E, Rompré PP, Potvin S. Antipsychotic agents for the treatment of substance use disorders in patients with and without comorbid psychosis. Journal of Clinical Psychopharmacology. 30: 417-24. PMID 20631559 DOI: 10.1097/Jcp.0B013E3181E7810A  0.582
2010 Zhornitsky S, Potvin S, Stip E, Rompré PP. Acute quetiapine dose-dependently exacerbates anhedonia induced by withdrawal from escalating doses of d-amphetamine. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 20: 695-703. PMID 20605419 DOI: 10.1016/J.Euroneuro.2010.04.011  0.535
2010 Stip E, Zhornitsky S, Potvin S, Tourjman V. Switching from conventional antipsychotics to ziprasidone: a randomized, open-label comparison of regimen strategies. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 34: 997-1000. PMID 20470848 DOI: 10.1016/J.Pnpbp.2010.05.010  0.575
Show low-probability matches.